Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 2506 AL 2520

Huntington's disease

Roze E, Bonnet C, Betuing S, Caboche J.

Adv Exp Med Biol. 2010;685:45-63.

Transcranial sonography in Huntington's disease

Krogias C, Eyding J, Postert T.

Int Rev Neurobiol. 2010;90:237-57. doi: 10.1016/S0074-7742(10)90017-2.

Unexpected combination of inherited chorea-acanthocytosis with MDR3 (ABCB4) defect mimicking Wilson's disease

Anheim M, Chamouard P, Rudolf G, Ellero B, Vercueil L, Goichot B, Marescaux C, Tranchant C.

Clin Genet. 2010 Sep;78(3):294-5. doi: 10.1111/j.1399-0004.2010.01386.x.

Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis

Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, Dietrich P, Volvert ML, Guillemot F, Dragatsis I, Bellaiche Y, Saudou F, Nguyen L, Humbert S.

Neuron. 2010 Aug 12;67(3):392-406. doi: 10.1016/j.neuron.2010.06.027.

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Chiu CT, Chuang DM.

Pharmacol Ther. 2010 Nov;128(2):281-304. doi: 10.1016/j.pharmthera.2010.07.006. Epub 2010 Aug 10.

The therapeutic potential of G-protein coupled receptors in Huntington's disease

Dowie MJ, Scotter EL, Molinari E, Glass M.

Pharmacol Ther. 2010 Nov;128(2):305-23. doi: 10.1016/j.pharmthera.2010.07.008. Epub 2010 Aug 11.

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

Walther S, Halpern M.

Pharmaceuticals (Basel). 2010 Aug 17;3(8):2689-2708. doi: 10.3390/ph3082689.

5-hydroxytryptamine subtype 6 receptor modulators: a patent survey

Ivachtchenko AV, Ivanenkov YA, Tkachenko SE.

Expert Opin Ther Pat. 2010 Sep;20(9):1171-96. doi: 10.1517/13543776.2010.494661.

A futility study of minocycline in Huntington's disease

Huntington Study Group DOMINO Investigators.

Mov Disord. 2010 Oct 15;25(13):2219-24. doi: 10.1002/mds.23236.

A comparison of two brief screening measures of cognitive impairment in Huntington's disease

Mickes L, Jacobson M, Peavy G, Wixted JT, Lessig S, Goldstein JL, Corey-Bloom J.

Mov Disord. 2010 Oct 15;25(13):2229-33. doi: 10.1002/mds.23181.

Substance abuse and movement disorders

Brust JC.

Mov Disord. 2010 Oct 15;25(13):2010-20. doi: 10.1002/mds.22599.

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT.

Ann Rheum Dis. 2010 Dec;69(12):2074-82. doi: 10.1136/ard.2010.130476. Epub 2010 Aug 19.

Opioid system functional regulation in neurological disease management

Nandhu MS, Naijil G, Smijin S, Jayanarayanan S, Paulose CS.

J Neurosci Res. 2010 Nov 15;88(15):3215-21. doi: 10.1002/jnr.22463.

The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus

Marcora E, Kennedy MB.

Hum Mol Genet. 2010 Nov 15;19(22):4373-84. doi: 10.1093/hmg/ddq358. Epub 2010 Aug 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias